Elicio Therapeutics

Access the latest articles, publications, and posters that demonstrate the power of Elicio's lymph node-targeted platform.

The senior accounting manager reports to the controller and manages general accounting and financial reporting processes under US GAAP, including monthly close, SEC filings, balance sheet analysis, and external audit support.

Dr. Christopher Haqq joined Elicio Therapeutics as executive vice president, head of research and development, and chief medical officer in October 2019, bringing more than 20 years of drug development leadership.

Esther Welkowsky leads clinical development trial operations, including clinical operations, supply chain, data management, clinical sample logistics, and safety operations. She has 20 years of clinical research experience.

Dr. Julian Adams has more than 40 years of experience in oncology research, development, and leadership. Before retiring in October 2022, Dr. Julian Adams was CEO of Gamida Cell (NASDAQ:GMDA) and oversaw approval of Omisirge (omidubicel).

Lisa McNeil, PhD, leads Elicio’s clinical immunogenicity program and supports preclinical assay development in oncology and infectious disease. She has more than 15 years of translational immunology research and clinical development experience.

Elicio has lymph node-targeted technology.

Elicio is a clinical-stage biotechnology company harnessing the power of the lymph nodes to amplify the immune response in the fight against cancer.

Elicio Therapeutics' privacy policy describes its practices for collecting, using, and disclosing information.